StockData
GENELUX Corp logo

GENELUX Corp (GNLX) stock

GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.17−0.11 (-4.82%)

Close on Nov 20, 2026Market cap $98.18MP/E –Yield –

Genelux free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Genelux's free cash flow for the twelve months ending Jun 30, 2026 was -$28.68M. For fiscal 2025 it was -$26.37M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$26.37M–
FY2024Dec 31, 2024-$21.61M–
FY2023Dec 31, 2023-$21.30M–
FY2022Dec 31, 2022-$3.62M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.98M–
Q1 FY2026Mar 31, 2026-$6.98M–
Q4 FY2025Dec 31, 2025-$6.64M–
Q3 FY2025Sep 30, 2025-$7.09M–
Q2 FY2025Jun 30, 2025-$7.17M–
Q1 FY2025Mar 31, 2025-$5.47M–
Q4 FY2024Dec 31, 2024-$4.40M–
Q3 FY2024Sep 30, 2024-$5.78M–
Q2 FY2024Jun 30, 2024-$7.05M–
Q1 FY2024Mar 31, 2024-$4.38M–
Q4 FY2023Dec 31, 2023-$7.15M–
Q3 FY2023Sep 30, 2023-$3.63M–
Q2 FY2023Jun 30, 2023-$5.81M–
Q1 FY2023Mar 31, 2023-$4.70M-267.2%
Q4 FY2022Dec 31, 2022-$1.52M–
Q3 FY2022Sep 30, 2022-$2.50M–
Q2 FY2022Jun 30, 2022-$2.41M–
Q1 FY2022Mar 31, 2022$2.81M–

More Genelux figures

See a number that looks wrong?